{"nctId":"NCT01084265","briefTitle":"A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism","startDateStruct":{"date":"2004-02"},"conditions":["Hypogonadism"],"count":31,"armGroups":[],"interventions":[{"name":"Recombinant human luteinizing hormone (r-hLH)","otherNames":["Luveris (r-hLH)"]},{"name":"Recombinant human follicle-stimulating hormone (r-hFSH)","otherNames":["Gonal-F (r-hFSH)"]},{"name":"Human chorionic gonadotropin (hCG)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be premenopausal, between 18 and 39 years of age\n* Have a clinical history of hypogonadotropic hypogonadism, and laboratory test result comply with diagnosis of hypogonadotropic hypogonadism during screening procedure\n* Have discontinued gonadotropins, gonadotropin-releasing hormone (GnRH) (gonadotropin naïve), or estrogen progesterone replacement therapy at least one month before the screening procedure\n* Have a negative progestin challenge test performed during screening\n* Have the following hormonal values in a centrally analyzed fasting blood sample, drawn within 6 months before initiation of treatment:\n* Follicular stimulating hormone (FSH): \\< 5 international units/liter (IU/L)\n* Luteinizing hormone (LH): \\< 1.2 IU/L\n* Oestradiol (E2): \\< 60 picogram/milliliter (pg/mL) (\\<220 picomolar/liter \\[pmol/L\\])\n* Prolactin (PRL): \\< 44.3 nanogram/milliliter (ng/mL) (\\< 1040 milli-international units/liter \\[mIU/L\\])\n* Thyrotrophin-stimulating hormone (TSH): \\< 6.5 micro-international units (uIU/mL)\n* Free Thyroxine (T4): 0.8-1.8 nanogram/deciliter (ng/dL) (11-24 pmol/L)\n* Triiodothyronine (T3): \\< 1.0 ng/mL (\\< 3.5 nanomolar/liter \\[nmol/L\\])\n* Have an endovaginal pelvic ultrasound scan showing (i) no ovarian tumor and cyst \\< 2 centimeters (cm); (ii) no clinically significant uterine abnormality, and (iii) \\< 13 mm small follicles (mean diameter \\< 10 mm) on the largest section through each ovary\n* Have a normal cervical pap smear within 6 months of the initial visit\n* Have a body mass index (BMI) between 18.4 and 31.4 kilogram/meter square (kg/m\\^2)\n* Be willing and able to comply with the protocol for the duration of the study\n* Have given written informed consent prior to any study related procedure\n\nExclusion Criteria:\n\n* Ongoing pregnancy\n* Any chronic systemic disease\n* Hypersensitive to study drug and control drug\n* History of severe ovarian hyperstimulation syndrome\n* Abnormal gynecological bleeding of undetermined origin\n* Previous or current hormone dependent tumor\n* Known active substance abuse or eating disorder\n* Known central nervous system (CNS) lesions: In cases where hypogonadotropic hypogonadism (HH) is secondary to a CNS lesion or its treatment, the subject will not be eligible without consulting Serono's Medical Director\n* Exercise program exceeding 10 hours per week\n* Currently undergoing treatment with psychotropic medication or with any other medication known to interfere with normal reproductive function (for example, neuroleptics, dopamine antagonists)\n* There is any abnormality, decided by investigators, which might produce effect on the absorption, distribution and excretion of investigational drug","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Met Both Index 1 and Index 2","description":"The three indices were defined as; Index 1: diameter of at least one follicle is greater than 17 mm; Index 2: serum oestradiol (E2) level in blood serum above 109 picogram/ milliliter (pg/mL) on human chorionic gonadotropin (hCG) injection day; Index 3: participant refuses to take hCG injection for the concern of ovarian hyperstimulation syndrome (OHSS) or participant is pregnant. A subset of these participants met Index 3.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had at Least One Follicle Greater Than 17mm in Diameter","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With E2 Level in Blood Serum Above 109 pg/mL on the Day of hCG Injection","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Refused to Take hCG Injection","description":"Participant refused to take hCG injection for the concern of OHSS or the participant was pregnant.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Number of Follicles With Diameter in the Range of 10-17 mm on the Day of hCG Injection in Treatment Cycle","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.57","spread":"4.07"}]}]}]},{"type":"SECONDARY","title":"Mean Number of Follicles With the Diameter Above 17 mm on the Day of hCG Injection in Treatment Cycle","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"2.00"}]}]}]},{"type":"SECONDARY","title":"Average Change of E2 Level in Participants Per Day up to Day 14","description":"The average change was calculated by assessing the E2 levels on 4 timepoints until day 14 (day 1, day 5, day 10, day 14 \\[hCG administration day\\]).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.03","spread":"64.53"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies","description":"Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy. Clinical pregnancy was defined as a pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":[]}}}